We focus on pioneering science with transformative, and even curative, potential.
Help redefine what’s possible in rare disease in the US
At Alexion, AstraZeneca Rare Disease, we are driven by a mission to change what it means to live with a rare disease. For individuals who want their work to matter, this is an opportunity to bring innovation to communities with profound unmet need and help expand access to life-changing medicines.
With a legacy of scientific firsts, deep partnership with patients and caregivers, and the global strength of AstraZeneca, Alexion offers the chance to be part of something bigger: helping deliver the next wave of rare disease innovation to the patients, providers and health systems who need it most.
Our US Rare Disease Area Groups Include:
- Rare Hematology & Nephrology
- Rare Neurology
- Rare Endocrinology & Rare Tumors
Make a difference where the need is greatest
Rare disease is one of the most unique areas in healthcare. Of the 10,000 known rare diseases, 90% still do not have an approved treatment. Patients and families often face long diagnostic journeys, limited awareness, and significant barriers to care.
That is why our mission matters.
At Alexion, we listen to and partner with the rare disease community to help improve outcomes for more patients in need. That means you’ll have the opportunity to work in an environment where every conversation has purpose and where your role can support awareness, education, and access in areas of high unmet need.
Join a company built on pioneering science
Alexion has more than 30 years of rare disease leadership and more than 20 years of real-world evidence. Today, that legacy includes 6 US approved medicines across 7 rare diseases, with an ambition to deliver five new medicines globally by 2030.
We are known for pursuing bold science in areas where progress has been limited, including a history of leadership in complement biology and a pipeline that spans multiple therapeutic areas such as hematology, nephrology, neurology, bone metabolism, endocrinology, and rare tumors.
Put patients at the center of everything
At Alexion, patient centricity is not a slogan. It is a mindset embedded across the organization, from development through delivery. We partner with patients and caregivers to understand their lived experiences and incorporate those insights into decision-making. That commitment shapes how we think, how we work, and how we show up for the communities we serve.
For commercial teams, this creates a culture where success is not only measured by performance, but by how well we understand the broader ecosystem and contribute to better experiences for patients, caregivers, and providers.
The strength of Alexion. The scale of AstraZeneca. The opportunity to grow.
As part of AstraZeneca, Alexion combines deep rare disease expertise with the scale, infrastructure, and global reach of one of the world’s leading biopharmaceutical companies. It offers the best of both worlds: the agility and entrepreneurial spirit of a focused rare disease business, together with strong investment in innovation and broader opportunities for career development.
As Alexion grows, so do the opportunities for employees to grow with it. We emphasize professional development, capability building, and internal mobility, with access to learning experiences across both Alexion and AstraZeneca. That means the chance to deepen expertise in specialty and rare disease, contribute to launch excellence, build experience in a high-science, high-impact environment, and grow within a broader enterprise over time.
This is an opportunity to join a company with strong momentum in rare disease and a culture that rewards strategic thinking, clinical credibility, and purposeful engagement.
The five key reasons to join at Alexion 
Make your mark where it matters most — Apply now
Cell therapy is a unique modality – by engineering living cells to precisely target disease we have the potential to transform patient outcomes across multiple therapeutic areas. At AstraZeneca, we are pioneering cell therapy at scale, investing in state-of-the-art platforms, building global capabilities and pushing the boundaries of science. Our aim is to ensure many more patients can benefit from cell therapy worldwide.
Craig Maxwell-
Our Disease Area Group
We look to apply our rare disease expertise where it's needed most, and where we can make the biggest impact for people living with rare diseases. This often means we are exploring disease states where scientific progress has stalled for decades, and where patients have limited, or zero, treatment options. Our Rare Disease Area Groups include:
- Rare Haematology, Nephrology & Transplant
- Rare Neurology
- Rare Bone & Endocrine Disorders
- Rare Cardiology & Amyloidosis
- Rare Tumours
Our Approach - Following the Science, Every Day
A Patient-First Philosophy
Developing life changing medicines for rare diseases requires scientific expertise as well as deep knowledge of the patient experience. We put patients at the center of our work every day, through our people, processes and metrics.
Continuous Innovation
Rare disease R&D presents unique challenges that require continuous innovation to deliver new treatments for patients. Driven by our patient-first approach, we continue to tailor our R&D process and develop new tools and methods to gain a deeper understanding of rare conditions and the needs people living with them face.
Our R&D capabilities
Our R&D philosophy listen, understand and respond to the communities we serve. We have proven what's possible in a variety of rare diseases and we continue to advance our science to help patients and families fully live their best lives.
